Japan To Establish iPS Medical Research Safety Guidelines
This article was originally published in PharmAsia News
Executive Summary
A research team at the Ministry of Health, Labor and Welfare is drafting guidelines addressing safety issues for using induced pluripotent stem cells in regenerative medicine. The guidelines will standardize issues related to generating and managing iPS cells for clinical studies; the purpose is to minimize adverse effects and carcinogenic risks. The Ministry aims to establish formal guidelines within 2010. It will be the world's first safety guidelines targeting iPS cells. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.